Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.23.1
Consolidated Balance Sheets - USD ($)
Feb. 28, 2023
Nov. 30, 2022
Current Assets    
Cash and cash equivalents $ 1,373,099 $ 1,703,958
Marketable securities 840,277 17,620
Accounts receivable (net of allowance for doubtful accounts of $3,580,233 and $3,528,119, respectively) 6,522,456 6,043,941
Prepaid expenses 580,144 566,557
Inventory, current portion 900,052 851,230
Other current assets 421,083 426,879
Total current assets 10,637,111 9,610,185
Property and Equipment-net 14,426,725 13,603,115
Other Assets    
Duke license agreement 13,450,834 13,691,028
Intangible assets, net 1,439,217 1,463,312
Inventory, net of current portion 8,996,063 9,275,344
Goodwill 1,941,411 1,941,411
Deferred tax assets 13,742,399 13,742,399
Operating lease right-of-use asset 526,710 606,034
Deposits and other assets, net 665,565 647,226
Total other assets 41,070,199 41,674,754
Total assets 66,134,035 64,888,054
Current Liabilities    
Accounts payable 2,363,757 1,605,301
Accrued expenses 3,074,903 3,585,810
Note payable 158,456 150,527
Line of credit 1,772,728 2,272,728
Current portion of operating lease liability 288,902 297,691
Current portion of Duke license agreement liability 2,000,000 1,983,036
Deferred revenue 9,253,131 9,586,327
Total current liabilities 18,911,877 19,481,420
Other Liabilities    
Deferred revenue, net of current portion 37,246,889 36,000,059
Contingent consideration 998,003 1,162,704
Note payable, net of current portion and debt issuance costs 8,547,744 8,579,875
Operating lease long-term liability 242,039 313,298
Long-term liability - revenue sharing agreements 875,000 875,000
Total other liabilities 47,909,675 46,930,936
Total liabilities 66,821,552 66,412,356
Commitments and contingencies (Note 9) 0 0
Stockholders' Deficit    
Preferred stock 0 0
Common stock ($.01 par value, 20,000,000 authorized; 14,848,001 issued and 8,443,230 outstanding as of February 28, 2023 and 14,848,001 issued and 8,500,511 outstanding as of November 30, 2022) 148,480 148,480
Additional paid-in capital 42,910,554 42,597,380
Treasury stock, at cost (22,875,850) (22,632,649)
Accumulated deficit (20,870,701) (21,637,513)
Total stockholders' deficit (687,517) (1,524,302)
Total liabilities and stockholders' equity 66,134,035 64,888,054
Series A Junior Participating Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock 0 0
Tianhe Stem Cell Biotechnologies Inc [Member]    
Other Assets    
Investment $ 308,000 $ 308,000